IL317609A - Il-12 variants, anti-pd1 antibodies, fusion proteins, and uses thereof - Google Patents

Il-12 variants, anti-pd1 antibodies, fusion proteins, and uses thereof

Info

Publication number
IL317609A
IL317609A IL317609A IL31760924A IL317609A IL 317609 A IL317609 A IL 317609A IL 317609 A IL317609 A IL 317609A IL 31760924 A IL31760924 A IL 31760924A IL 317609 A IL317609 A IL 317609A
Authority
IL
Israel
Prior art keywords
seq
acid sequence
amino acid
variant
antibody
Prior art date
Application number
IL317609A
Other languages
Hebrew (he)
Inventor
James Reasoner Apgar
Riggers Javier Fernando Chaparro
Ling Hon Matthew Chu
Tzu-Hsuan Huang
Kritika Mohan
Lidia Mosyak
Edward Derrick Pascua
James Travis Patterson
Gabriel Roy Starbeck-Miller
Dirk Michael Zajonc
Original Assignee
Pfizer
James Reasoner Apgar
Riggers Javier Fernando Chaparro
Ling Hon Matthew Chu
Huang Tzu Hsuan
Kritika Mohan
Lidia Mosyak
Edward Derrick Pascua
James Travis Patterson
Starbeck Miller Gabriel Roy
Dirk Michael Zajonc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer, James Reasoner Apgar, Riggers Javier Fernando Chaparro, Ling Hon Matthew Chu, Huang Tzu Hsuan, Kritika Mohan, Lidia Mosyak, Edward Derrick Pascua, James Travis Patterson, Starbeck Miller Gabriel Roy, Dirk Michael Zajonc filed Critical Pfizer
Publication of IL317609A publication Critical patent/IL317609A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Claims (35)

1. 93
2. CLAIMS It is claimed: 1. An isolated human interleukin 12 (IL-12) variant comprising an amino acid substitution at position Y167 of SEQ ID NO: 1 (IL-12 p35 subunit) and position D93 of SEQ ID NO: 2 (IL-12 p40 subunit). 2. The IL-12 variant of claim 1, wherein the Y167 substitution is Y167A
3. The IL-12 variant of any one of claims 1-2, wherein the D93 substitution is D93L
4. The IL-12 variant of any one of claims 1-3, wherein the Y167 substitution is Y167A and the D93 substitution is D93L.
5. The IL-12 variant of any one of claims 1-4, wherein the p40 subunit further comprises one or more mutations to reduce the binding of IL-12 to heparin.
6. The IL-12 variant of claim 5, wherein the mutations to reduce the binding of IL-to heparin comprise the substitutions K258G, S259G, and K260G, and deletions of R261, E262, K263, and K264 of SEQ ID NO: 2.
7. An isolated human interleukin 12 (IL-12) variant comprising one or both of i) a polypeptide comprising the amino acid sequence of SEQ ID NO: 3 (variant IL-12 psubunit) and ii) a polypeptide comprising the amino acid sequence of SEQ ID NO: (variant IL-12 p40 subunit).
8. An isolated human interleukin 12 (IL-12) variant comprising an amino acid substitution at one or more of positions: F39 of SEQ ID NO: 1 (IL-12 p35 subunit), Iof SEQ ID NO: 1, Y167 of SEQ ID NO: 1, K85 of SEQ ID NO: 2 (IL-12 p40 subunit) and D93 of SEQ ID NO: 2.
9. The IL-12 variant of claim 8, wherein the F39 substitution is F39R or F39A, the Isubstitution is I52E, I52R, or I52H, the Y167 substitution is Y167A, the Ksubstitution is K85E, and the D93 substitution is D93L.
10. The IL-12 variant of any one of claims 8-9, wherein the p40 subunit further comprises one or more mutations to reduce the binding of IL-12 to heparin. 94
11. The IL-12 variant of any one of claims 1-10, wherein the IL-12 variant has reduced activity as compared to wild-type human IL-12.
12. An isolated antibody that binds to PD1 and comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH CDR1 comprises the amino acid sequence of SEQ ID NOs: 9, 35, or 36, the VH CDR2 comprises the amino acid sequence of SEQ ID NO: 10 or 37, the VH CDR3 comprises the amino acid sequence of SEQ ID NO: 11, the VL CDR1 comprises the amino acid sequence of SEQ ID NO: 12, the VL CDR2 comprises the amino acid sequence of SEQ ID NO: 13, and the VL CDR3 comprises the amino acid sequence of SEQ ID NO: 14.
13. The antibody of claim 12, wherein the VH comprises the amino acid sequence of SEQ ID NO: 7 and the VL comprises the amino acid sequence of SEQ ID NO: 8.
14. An isolated antibody comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 5, 51 or 52 and a light chain comprising the amino acid sequence of SEQ ID NO: 6, wherein the C-terminal lysine of SEQ ID NO: 5, 51, or is optional.
15. An isolated antibody that binds to PD1 and comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH CDR1 comprises the amino acid sequence of SEQ ID NO: 19, 35, or 36, the VH CDR2 comprises the amino acid sequence of SEQ ID NO: 20 or 37, the VH CDR3 comprises the amino acid sequence of SEQ ID NO: 21, the VL CDR1 comprises the amino acid sequence of SEQ ID NO: 22, the VL CDR2 comprises the amino acid sequence of SEQ ID NO: 23, and the VL CDR3 comprises the amino acid sequence of SEQ ID NO: 24.
16. An isolated antibody that binds to PD1 and comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH CDR1 comprises the amino acid sequence of SEQ ID NO: 9, 35, or 36, the VH CDR2 comprises the amino acid sequence of SEQ ID NO: 38 or 39, the VH CDR3 comprises the amino acid sequence of SEQ ID NO: 21, the VL CDR1 comprises the amino acid sequence of SEQ ID NO: 12, the VL CDR2 comprises the amino acid sequence of SEQ ID NO: 40, and the VL CDR3 comprises the amino acid sequence of SEQ ID NO: 41. 95
17. The antibody of any one of claims 12-16, wherein the antibody does not block the binding of PDL1 to PD1.
18. An isolated fusion protein comprising a human interleukin 12 (IL-12) variant of any one of claims 1-11 linked to an anti-PD1 antibody.
19. The fusion protein of claim 18, wherein the anti-PD1 antibody is the antibody of any one of claims 12-16.
20. The fusion protein of any one of claims 18-19, wherein the IL-12 variant comprises an amino acid substitution at position Y167 of SEQ ID NO: 1 (IL-12 psubunit) and position D93 of SEQ ID NO: 2 (IL-12 p40 subunit).
21. The fusion protein of any one of claims 18-20, wherein the antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises the amino acid sequence of SEQ ID NO: 7 and the VL comprises the amino acid sequence of SEQ ID NO: 8.
22. An isolated fusion protein comprising a human interleukin 12 (IL-12) variant and an anti-PD1 antibody, wherein the fusion protein comprises the polypeptides of SEQ ID NOs: 5, 25, 6, and 4.
23. An isolated fusion protein comprising a human interleukin 12 (IL-12) variant and an anti-PD1 antibody, wherein the fusion protein comprises the polypeptides of SEQ ID NOs: 15, 26, 16, and 4.
24. An isolated polynucleotide or polynucleotides comprising one or more nucleotide sequences encoding one or more of the IL-12 variants, anti-PD1 antibodies, fusion proteins or a polypeptide thereof of any one of claims 1-23.
25. An isolated polynucleotide or polynucleotides comprising one or more nucleotide sequences of encoding a human interleukin 12 (IL-12) variant comprising an amino acid substitution at position Y167 of SEQ ID NO: 1 (IL-12 p35 subunit) and position D93 of SEQ ID NO: 2 (IL-12 p40 subunit), wherein the one or more nucleotide sequences comprise a nucleotide sequence of SEQ ID NO: 44 and a nucleotide sequence of SEQ ID NO: 45. 96
26. An isolated polynucleotide or polynucleotides comprising one or more nucleotide sequences encoding the VH, VL, or both of an antibody that binds PD1, wherein the polynucleotide(s) comprise the VH nucleic acid sequence of SEQ ID NO: 46, the VL nucleic acid sequence of SEQ ID NO: 47, or both the VH nucleic acid sequence of SEQ ID NO: 46 and the VL nucleic acid sequence of SEQ ID NO: 47.
27. An isolated polynucleotide or polynucleotides comprising one or more nucleotide sequences encoding any one or more of the heavy chain, light chain, IL-12 psubunit, or heavy chain-IL12 p35 fusion polypeptide of a fusion protein comprising a human IL-12 variant and an anti-PD1 antibody, wherein the polynucleotide(s) comprise the heavy chain nucleic acid sequence of SEQ ID NO: 48, the light chain nucleic acid sequence of SEQ ID NO: 50, the IL-12 p40 subunit nucleic acid sequence of SEQ ID NO: 45, the heavy chain-IL12 p35 fusion polypeptide nucleic acid sequence of SEQ ID NO: 49 or each of the heavy chain nucleic acid sequence of SEQ ID NO: 48, the light chain nucleic acid sequence of SEQ ID NO: 50, the IL-p40 subunit nucleic acid sequence of SEQ ID NO: 45, and the heavy chain-IL12 pfusion polypeptide nucleic acid sequence of SEQ ID NO: 49.
28. An isolated polynucleotide or polynucleotides comprising one or more nucleotide sequences encoding any one or more of the heavy chain, light chain, IL-12 psubunit, or heavy chain-IL12 p35 fusion polypeptide of a fusion protein comprising a human IL-12 variant and an anti-PD1 antibody, wherein the polynucleotide(s) comprise the heavy chain encoding nucleic acid sequence of the insert of the plasmid deposited with the ATCC and having ATCC Accession Number PTA-127517, the light chain encoding nucleic acid sequence of the insert of the plasmid deposited with the ATCC and having ATCC Accession Number PTA-127519, the IL-p40 subunit encoding nucleic acid sequence of the insert of the plasmid deposited with the ATCC and having ATCC Accession Number PTA-127520, the heavy chain-IL12 p35 fusion polypeptide encoding nucleic acid sequence of the insert of the plasmid deposited with the ATCC and having ATCC Accession Number PTA-1275, or each of the heavy chain encoding nucleic acid sequence of the insert of the plasmid deposited with the ATCC and having ATCC Accession Number PTA-127517, the light chain encoding nucleic acid sequence of the insert of the plasmid deposited with the ATCC and having ATCC Accession Number PTA-127519, the IL-p40 subunit encoding nucleic acid sequence of the insert of the plasmid deposited with the ATCC and having ATCC Accession Number PTA-127520, and the heavy chain-IL12 p35 fusion polypeptide encoding nucleic acid sequence of the insert of the 97 plasmid deposited with the ATCC and having ATCC Accession Number PTA-127518.
29. A vector comprising the polynucleotide or polynucleotides of any one of claims 24-28.
30. An isolated host cell comprising the polynucleotide or polynucleotides of any one of claims 24-28 or the vector of claim 29.
31. A method of producing an IL-12 variant, anti-PD1 antibody, or fusion protein comprising culturing the host cell of claim 30 under conditions that result production of the IL-12 variant, anti-PD1 antibody, or fusion protein, and optionally further recovering the IL-12 variant, anti-PD1 antibody, or fusion protein.
32. A pharmaceutical composition comprising the IL-12 variant, anti-PD1 antibody, or fusion protein of any one of claims 1-23 and a pharmaceutically acceptable carrier.
33. The IL-12 variant, anti-PD1 antibody, or fusion protein of any one of claims 1-or the pharmaceutical composition of claim 32 for use as a medicament, optionally for use as a medicament for the treatment of cancer.
34. The IL-12 variant, anti-PD1 antibody, fusion protein, or pharmaceutical composition for use of claim 33 wherein the cancer is bladder cancer, breast cancer, clear cell kidney cancer, head/neck squamous cell carcinoma [squamous cell carcinoma of the head and neck (SCCHN)], lung squamous cell carcinoma, lung adenocarcinoma, malignant melanoma, non-small-cell lung cancer (NSCLC), ovarian cancer, pancreatic cancer, prostate cancer, renal cell carcinoma (RCC), small-cell lung cancer (SCLC), triple negative breast cancer, urothelial cancer, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, Hodgkin’s lymphoma (HL), mantle cell lymphoma (MCL), multiple myeloma (MM), myeloid cell leukemia-1 protein (Mcl-1), myelodysplastic syndrome (MDS), non-Hodgkin’s lymphoma (NHL), small lymphocytic lymphoma (SLL), endometrial cancer, B-cell acute lymphoblastic leukemia, colorectal cancer (CRC), glioblastoma, uterine cancer, cervical cancer, penile cancer, gastric cancer (GC) or non-melanoma skin cancer. 98
35. The IL-12 variant, anti-PD1 antibody, fusion protein, or pharmaceutical composition for use of claim 33 or 34, wherein the cancer was previously treated with a PD(L)1 inhibitor which is different than the anti-PD1 antibody of any one of claims 12-17.
IL317609A 2022-06-17 2023-06-14 Il-12 variants, anti-pd1 antibodies, fusion proteins, and uses thereof IL317609A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263353241P 2022-06-17 2022-06-17
US202363496545P 2023-04-17 2023-04-17
PCT/IB2023/056152 WO2023242769A1 (en) 2022-06-17 2023-06-14 Il-12 variants, anti-pd1 antibodies, fusion proteins, and uses thereof

Publications (1)

Publication Number Publication Date
IL317609A true IL317609A (en) 2025-02-01

Family

ID=86899441

Family Applications (1)

Application Number Title Priority Date Filing Date
IL317609A IL317609A (en) 2022-06-17 2023-06-14 Il-12 variants, anti-pd1 antibodies, fusion proteins, and uses thereof

Country Status (13)

Country Link
US (1) US20240010696A1 (en)
EP (1) EP4540278A1 (en)
JP (1) JP2025520411A (en)
KR (1) KR20250010064A (en)
CN (1) CN120035602A (en)
AU (1) AU2023294103A1 (en)
CA (1) CA3259654A1 (en)
CO (1) CO2024017318A2 (en)
IL (1) IL317609A (en)
MX (1) MX2024015610A (en)
PE (1) PE20250875A1 (en)
TW (1) TW202409067A (en)
WO (1) WO2023242769A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200089312A (en) 2017-11-28 2020-07-24 추가이 세이야쿠 가부시키가이샤 Ligand binding molecule capable of modulating ligand binding activity
EP3981428A4 (en) 2019-06-05 2023-07-12 Chugai Seiyaku Kabushiki Kaisha PROTEAS SUBSTRATE AND POLYPEPTIDE WITH PROTEAS CLEAVAGE SEQUENCE
CN115943210A (en) 2020-01-20 2023-04-07 中外制药株式会社 ligand-binding fusion protein
WO2024148369A1 (en) * 2023-01-07 2024-07-11 Lyell Immunopharma, Inc. Targeted il-12 affinity variants
CN120230225A (en) * 2024-02-07 2025-07-01 上海交通大学 Activity-regulatable IL-12 fusion protein and its use
WO2025252212A1 (en) * 2024-06-07 2025-12-11 福佑泰生物制药公司 Immunoconjugate of anti-pd-1 antibody and cytokine il-12 mutant protein, and use thereof
CN120077060A (en) * 2024-08-16 2025-05-30 程联胜 Interleukin 12 mutants and uses thereof
US20260083857A1 (en) * 2024-09-23 2026-03-26 Cephalon Llc Anti-pd-1 antibody-attenuated il-2 immunoconjugate formulations

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
JP2002522063A (en) 1998-08-17 2002-07-23 アブジェニックス インコーポレイテッド Generation of modified molecules with increased serum half-life
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
AR045563A1 (en) 2003-09-10 2005-11-02 Warner Lambert Co ANTIBODIES DIRECTED TO M-CSF
WO2006113546A2 (en) 2005-04-15 2006-10-26 Neogenix Oncology, Inc. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
US7923538B2 (en) 2005-07-22 2011-04-12 Kyowa Hakko Kirin Co., Ltd Recombinant antibody composition
SI1966238T1 (en) * 2005-12-30 2012-08-31 Merck Patent Gmbh Interleukin-12p40 variants with improved stability
CA2676529C (en) 2007-01-24 2014-03-25 Kyowa Kirin Co., Ltd. Genetically recombinant antibody composition having enhanced effector activity
SI2242771T1 (en) 2007-12-14 2013-09-30 Bristol-Myers Squibb Company Binding molecules to the human ox40 receptor
WO2011112935A2 (en) * 2010-03-12 2011-09-15 The Regents Of The University Of California Antibody fusion proteins with disrupted heparin-binding activity
SA112330278B1 (en) 2011-02-18 2015-10-09 ستيم سينتركس، انك. Novel modulators and methods of use
EP2780039B9 (en) 2011-11-17 2018-04-18 Pfizer Inc Cytotoxic peptides and antibody drug conjugates thereof
MX2016017393A (en) 2014-07-01 2017-09-05 Pfizer Bispecific heterodimeric diabodies and uses thereof.
TWI595006B (en) 2014-12-09 2017-08-11 禮納特神經系統科學公司 Anti-PD-1 antibodies and methods of using same
HUE057285T2 (en) 2015-04-13 2022-04-28 Pfizer Therapeutic antibodies and their uses
CN111148762A (en) 2017-05-31 2020-05-12 斯特库伯株式会社 Antibodies and molecules that immunospecifically bind to BTN1a1 and therapeutic uses thereof
JP7234142B2 (en) 2017-06-02 2023-03-07 ファイザー・インク Antibodies specific for FLT3 and uses thereof
KR102884523B1 (en) * 2018-10-03 2025-11-10 젠코어 인코포레이티드 IL-12 heterodimeric Fc-fusion protein
EP4037700A2 (en) * 2019-10-03 2022-08-10 Xencor, Inc. Targeted il-12 heterodimeric fc-fusion proteins
MX2022011676A (en) * 2020-03-23 2023-03-08 Zymeworks Bc Inc Masked il12 fusion proteins and methods of use thereof.
WO2022094046A1 (en) * 2020-10-29 2022-05-05 Proviva Therapeutics (Hong Kong) Limited Il-12 compositions and methods of use thereof
AU2022314734A1 (en) * 2021-07-19 2024-02-08 Regeneron Pharmaceuticals, Inc. Il12 receptor agonists and methods of use thereof
CA3232632A1 (en) * 2021-09-17 2023-03-23 Bicara Therapeutics Inc. Caix targeting il-12 fusion proteins and methods of use thereof

Also Published As

Publication number Publication date
CA3259654A1 (en) 2023-12-21
CO2024017318A2 (en) 2024-12-30
AU2023294103A1 (en) 2024-12-19
PE20250875A1 (en) 2025-03-28
JP2025520411A (en) 2025-07-03
KR20250010064A (en) 2025-01-20
MX2024015610A (en) 2025-02-10
WO2023242769A1 (en) 2023-12-21
EP4540278A1 (en) 2025-04-23
US20240010696A1 (en) 2024-01-11
TW202409067A (en) 2024-03-01
CN120035602A (en) 2025-05-23

Similar Documents

Publication Publication Date Title
ES3031002T3 (en) T cell recruiting polypeptides based on tcr alpha/beta reactivity
CN104403004B (en) Preparation and use of antibody-interferon heterodimer
AU2002357784B2 (en) Immunocytokines with modulated selectivity
US20200087377A1 (en) Multifunctional Fusion Protein and Applications Thereof
JP2024075737A5 (en)
EP4509186A2 (en) Anti-pd1 monoclonal antibody, pharmaceutical composition thereof and use thereof
JP5324593B2 (en) Inhibition of macrophage stimulating protein receptor (RON) and methods of treatment thereof
JP2022509065A5 (en)
JP2020511932A5 (en)
JP2022512043A5 (en)
AU2020289080A1 (en) Multispecific proteins
CN114514244B (en) T cell activating antibodies
EP3759229A1 (en) Use of a multimeric anti-dr5 binding molecule in combination with a chemotherapeutic agent for treating cancer
RU2018147423A (en) Anti-PD-L1 and IL-2 cytokines
CN113637692A (en) Immunomodulator
JP2019531764A5 (en)
RU2012139197A (en) MODIFIED ANTIGEN-BINDING MOLECULES WITH ALTERED CELL SIGNAL ACTIVITY
US20220298212A1 (en) Recombinant 4-1bb binding proteins and their use
JP2021528047A5 (en)
JP2021521110A5 (en)
JP2023523083A5 (en)
JP2016504420A5 (en)
CN117679505A (en) Drug combinations and uses
JP2020536492A5 (en)
WO2018055503A1 (en) Combination comprising a pd-1 antagonist and an fgfr4 inhibitor